SOPHiA GENETICS SA
SOPHiA GENETICS SA is a Switzerland-based company primarily engaged in the healthcare technology industry. The Company’s key product is SOPHiA DDM, which is a cloud-native software-as-a-service (SaaS) platform. The platform analyses multimodal data, including genomics, radiomics, clinical, biological, and digital pathology data, to generate actionable insights for patients with cancer or rare diseases, bringing the power of data-driven medicine to patients across the globe. Additionally, the Company aids BioPharma partners with artificial-intelligence-powered drug discovery, development, and deployment. The Company has offices in Switzerland, France, and the United States and operates worldwide.
Stock Performance Snapshot
Analyst Rating
Analysts strongly recommend buying SOPHiA GENETICS stock, predicting significant price growth ahead.
Financial Health
SOPHiA GENETICS demonstrates solid revenue and profitability, supported by healthy cash flow and margins.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Accenture plc
Provides consulting and technology services.
Adobe Systems Inc.
Develops software and cloud-based solutions for digital media and digital marketing.
Automatic Data Processing, Inc.
Provides business process outsourcing and technology services.
